Viking Therapeutics (VKTX) Corporate presentation summary

Strategic focus and pipeline overview

• Focused on developing novel therapeutics for metabolic and endocrine diseases, with multiple programs showing strong efficacy data.

• Lead asset VK2735, a dual GLP-1/GIP agonist, is in Phase 3 for obesity, with both injectable and oral formulations advancing.

• Additional pipeline includes VK3019 (amylin agonist for obesity), VK2809 (TRβ agonist for MASH), and VK0214 (TRβ agonist for X-ALD), all progressing through clinical stages.

VK2735 clinical development and efficacy

• VK2735 demonstrates differentiated pharmacokinetics and superior weight loss in preclinical and clinical studies compared to tirzepatide.

• Oral VK2735 achieved up to 12.2% mean weight loss after 13 weeks in Phase 2, with dose-dependent, progressive effects and no plateau observed.

• Subcutaneous VK2735 showed up to 14.7% mean weight loss in Phase 2, with durable effects and >90% efficacy retained four weeks post-treatment.

• Both oral and injectable forms exhibited promising safety and tolerability, with most adverse events mild to moderate and primarily gastrointestinal.

Maintenance, durability, and next steps

• Exploratory cohorts indicate lower maintenance doses can sustain or extend weight loss after induction.

• GI adverse events are most common early in treatment and tend to resolve over time, especially with titration.

• Phase 3 VANQUISH studies for subcutaneous VK2735 in obesity and type 2 diabetes are fully enrolled, with maintenance studies ongoing and results expected in 2026–2027.